Orchestra BioMed (NASDAQ: OBIO) revenue
Orchestra BioMed reported revenue of $33.5m for fiscal 2025, 1,169.2% more than in fiscal 2024 ($2.6m). Since fiscal 2022 its revenue has grown by 847.7%, an average growth of 111.6% a year.
Fiscal 2025 is the highest of the 4 fiscal years on record for Orchestra BioMed. The biggest drop was in fiscal 2023, −21.9%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $33.5m | +1,169.2% | −$51.8m | −154.7% |
| 2024 | $2.6m | −4.4% | −$64.3m | −2,437.5% |
| 2023 | $2.8m | −21.9% | −$51.5m | −1,866.2% |
| 2022 | $3.5m | — | −$32.7m | −924.3% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Orchestra BioMed revenue compared with its sector
By revenue for its latest fiscal year, Orchestra BioMed ranks 347th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Orchestra BioMed, 1,169.2%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 345th | X4 Pharmaceuticals | $35.1m | 1,250.5% |
| 346th | Precision Biosciences | $34.3m | −50.1% |
| 347th | Orchestra BioMed | $33.5m | 1,169.2% |
| 348th | Stereotaxis | $32.4m | 20.3% |
| 349th | EyePoint | $31.4m | −27.5% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Orchestra BioMed
- How much revenue did Orchestra BioMed make in fiscal 2025?
- Orchestra BioMed reported revenue of $33.5m for fiscal 2025, compared with $2.6m in fiscal 2024.
- How much has the revenue of Orchestra BioMed grown?
- Between fiscal 2022 and fiscal 2025 it went from $3.5m to $33.5m: 847.7% more, an average growth of 111.6% a year.
- What was the best year for revenue at Orchestra BioMed?
- Of its last 4 fiscal years, fiscal 2025, with $33.5m.
- Where does Orchestra BioMed rank in its sector by revenue?
- It ranks 347th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Orchestra BioMed come from?
- From the annual report (Form 10-K) that Orchestra BioMed files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Orchestra BioMed files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022. More on Orchestra BioMed: the Orchestra BioMed page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.